Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday

Larimar Therapeutics (NASDAQ:LRMR) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 12:30 PM ET.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.30). On average, analysts expect Larimar Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Larimar Therapeutics Trading Up 0.4%

Larimar Therapeutics stock opened at $4.49 on Monday. The firm has a market capitalization of $466.42 million, a price-to-earnings ratio of -2.03 and a beta of 0.90. The firm’s fifty day moving average price is $3.95 and its two-hundred day moving average price is $3.92. Larimar Therapeutics has a 1-year low of $1.61 and a 1-year high of $6.42.

Insider Activity

In other news, Director James E. Flynn bought 5,000,000 shares of the stock in a transaction dated Friday, February 27th. The stock was bought at an average price of $5.00 per share, for a total transaction of $25,000,000.00. Following the completion of the acquisition, the director directly owned 10,622,957 shares in the company, valued at approximately $53,114,785. This trade represents a 88.92% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Larimar Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its stake in Larimar Therapeutics by 75.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock valued at $33,000 after buying an additional 4,376 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Larimar Therapeutics by 7.8% in the second quarter. American Century Companies Inc. now owns 69,285 shares of the company’s stock valued at $200,000 after acquiring an additional 5,001 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Larimar Therapeutics by 26.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,008 shares of the company’s stock valued at $111,000 after acquiring an additional 6,038 shares in the last quarter. Barclays PLC increased its position in shares of Larimar Therapeutics by 10.7% during the fourth quarter. Barclays PLC now owns 78,470 shares of the company’s stock valued at $299,000 after acquiring an additional 7,577 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Larimar Therapeutics by 15.7% during the first quarter. Rhumbline Advisers now owns 65,018 shares of the company’s stock valued at $140,000 after acquiring an additional 8,818 shares during the last quarter. 91.92% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LRMR has been the topic of a number of analyst reports. Wedbush upped their target price on shares of Larimar Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Friday. Citigroup lifted their price target on Larimar Therapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Leerink Partners raised Larimar Therapeutics to a “strong-buy” rating in a report on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Thursday, January 22nd. Finally, Lifesci Capital upgraded Larimar Therapeutics to a “strong-buy” rating in a report on Tuesday, February 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $16.43.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.